Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15433943 | 0.91 | PIK3CA (0.46) | PIK3CAPIK3CGCREBBPSYKBRD4 | |
| SCHEMBL7881738 | 0.90 | PIK3CA (0.59) | PIK3CACREBBP | |
| SCHEMBL9612508 | 0.85 | PIK3CA (0.47) | PIK3CAPIK3CGFGFR1FGFR2FGFR3 | |
| SCHEMBL9612491 | 0.85 | PIK3CA (0.48) | PIK3CAPIK3CGFGFR1FGFR2FGFR3 | |
| SCHEMBL9612757 | 0.84 | PIK3CA (0.51) | PIK3CAPIK3CGFGFR1FGFR2FGFR3 | |
| SCHEMBL9612538 | 0.84 | PIK3CA (0.53) | PIK3CAPIK3CGCREBBP | |
| SCHEMBL9612499 | 0.84 | PIK3CA (0.53) | PIK3CAPIK3CGFGFR1FGFR2FGFR3 | |
| SCHEMBL9612534 | 0.83 | PIK3CA (0.53) | PIK3CAPIK3CGCREBBP | |
| SCHEMBL9612539 | 0.83 | PIK3CA (0.53) | PIK3CAPIK3CGCREBBP | |
| SCHEMBL15433948 | 0.83 | PIK3CA (0.53) | PIK3CAPIK3CGCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2012071509-A2 | BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885PIK3CG 10/4885FGFR1 1308/4885 |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885PIK3CG 10/4885FGFR1 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.